Four-Week, 8-Week CAB/RPV Injections Safe, Effective in Women Four-Week, 8-Week CAB/RPV Injections Safe, Effective in Women

Both the 8-week and 4-week treatment groups of women with HIV receiving cabotegravir and rilpivirine reported increased treatment satisfaction, and more than 90% achieved HIV-1 RNA below 50 copies/mL.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: HIV/AIDS News Source Type: news